Συγγραφείς:
Zinzani, P.L.
Chen, R.
Armand, P.
Johnson, N.A.
Brice, P.
Radford, J.
Ribrag, V.
Molin, D.
Vassilakopoulos, T.P.
Tomita, A.
von Tresckow, B.
Shipp, M.A.
Lin, J.
Nahar, A.
Balakumaran, A.
Moskowitz, C.H.
Λέξεις-κλειδιά:
brentuximab vedotin; pembrolizumab; antibody conjugate; brentuximab vedotin; monoclonal antibody; pembrolizumab, adult; adverse drug reaction; allogeneic stem cell transplantation; autologous stem cell transplantation; bone marrow transplantation; cancer regression; cancer survival; classical Hodgkin lymphoma; clinical assessment; clinical effectiveness; clinical evaluation; cohort analysis; colitis; cytokine release syndrome; disease exacerbation; drug efficacy; drug safety; drug withdrawal; epilepsy; female; follow up; graft versus host reaction; human; hyperthyroidism; hypothyroidism; incidence; infusion related reaction; iritis; Letter; leukemia relapse; major clinical study; male; monotherapy; myocarditis; myositis; overall survival; pneumonia; priority journal; progression free survival; salvage therapy; sarcoidosis; treatment duration; treatment response; treatment response time; treatment withdrawal; autotransplantation; hematopoietic stem cell transplantation; Hodgkin disease; stem cell transplantation; tumor recurrence, Antibodies, Monoclonal, Humanized; Brentuximab Vedotin; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous
